Page last updated: 2024-12-08

n(6)-methyl-2'-deoxyadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(6)-methyl-2'-deoxyadenosine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID168948
CHEMBL ID1875918
CHEBI ID7417
SCHEMBL ID548569
MeSH IDM0126217

Synonyms (38)

Synonym
adenosine, 2'-deoxy-n-methyl-
nsc-66392
PDSP2_000995
PDSP1_001011
2002-35-9
n6-methyl-2'-deoxyadenosine
C03795 ,
NCGC00163306-01
2'-deoxy-n6-methylado
bdbm82036
(2r,3s,5r)-2-(hydroxymethyl)-5-[6-(methylamino)purin-9-yl]oxolan-3-ol
n(6)-methyl-2'-deoxyadenosine
n(6)-me-dado
2'-deoxy-n(6)-methyladenosine
unii-48qzw2ir9h
48qzw2ir9h ,
nsc 66392
n6-me-dado
adenosine,2'-deoxy-n-methyl-
HG1034
SCHEMBL548569
(2r,3s,5r)-2-(hydroxymethyl)-5-[6-(methylamino)purin-9-yl]tetrahydrofuran-3-ol
(2r,3s,5r)-2-(hydroxymethyl)-5-(6-(methylamino)-9h-purin-9-yl)tetrahydrofuran-3-ol
AKOS024260286
CHEBI:7417 ,
2'-deoxy-n6-methyladenosine
n6-methyldeoxyadenosine
6-(methylamino)purine deoxyriboside
CHEMBL1875918
mfcd00055999
DTXSID60173840
AC-8212
AS-59789
(2r,3s,5r)-2-(hydroxymethyl)-5-[6-(methylamino)-9h-purin-9-yl]oxolan-3-ol
Q27107487
A879876
CS-W012441
(2r,3s)-2-hydroxymethyl-5-((s)-6-methylamino-purin-9-yl)-tetrahydro-furan-3-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine 2'-deoxyribonucleosideA 2'-deoxyribonucleoside that has a purine moiety as the nucleobase (the R group in the illustration).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency18.20030.000811.382244.6684AID686978; AID686979
regulator of G-protein signaling 4Homo sapiens (human)Potency0.13370.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1578771Antimalarial activity against Plasmodium falciparum FCQ-27 isolate infected in erythrocytes assessed as reduction in [G-3H]Hypoxanthine incorporation incubated for 24 hrs followed by addition of [G-3H]Hypoxanthine and measured after 18 to 20 hrs by scinti2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.92 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]